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The T cell lineage is commonly divided into CD4-expressing helper T cells that polarize 
immune responses through cytokine secretion and CD8-expressing cytotoxic T cells that 
eliminate infected target cells by virtue of the release of cytotoxic molecules. Recently, a 
population of CD4+ T cells that conforms to the phenotype of cytotoxic CD8+ T cells has 
received increased recognition. These cytotoxic CD4+ T cells display constitutive expres-
sion of granzyme B and perforin at the protein level and mediate HLA class II-dependent 
killing of target cells. In humans, this cytotoxic profile is found within the human cytomeg-
alovirus (hCMV)-specific, but not within the influenza- or Epstein–Barr virus-specific CD4+ 
T cell populations, suggesting that, in particular, hCMV infection induces the formation 
of cytotoxic CD4+ T  cells. We have previously described that the transcription factor 
Homolog of Blimp-1 in T cells (Hobit) is specifically upregulated in CD45RA+ effector 
CD8+ T cells that arise after hCMV infection. Here, we describe the expression pattern 
of Hobit in human CD4+ T cells. We found Hobit expression in cytotoxic CD4+ T cells 
and accumulation of Hobit+ CD4+ T cells after primary hCMV infection. The Hobit+ CD4+ 
T cells displayed highly overlapping characteristics with Hobit+ CD8+ T cells, including 
the expression of cytotoxic molecules, T-bet, and CX3CR1. Interestingly, γδ+ T  cells 
that arise after hCMV infection also upregulate Hobit expression and display a similar 
effector phenotype as cytotoxic CD4+ and CD8+ T cells. These findings suggest a shared 
differentiation pathway in CD4+, CD8+, and γδ+ T  cells that may involve Hobit-driven 
acquisition of long-lived cytotoxic effector function.
Keywords: hobit, cytotoxic, cD4+ T cells, human cytomegalovirus, human
inTrODUcTiOn
After activation, CD4+ T cells differentiate into various subsets that can be distinguished based 
on their unique cytokine milieu and transcription factor profile. To date, numerous T helper (TH) 
subsets have been described, including TH1, TH2, TH17, and T follicular helper CD4+ T cells (1–3). 
Classically, CD4+ T cells are referred to as cells that exert their helper functions to support other 
immune cells in their activation and maintenance. For example, CD4+ T  cells assist B  cells in 
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inducing antibody class switching and establishing germinal 
centers through the secretion of cytokines (4). On the other 
hand, the capacity to lyse infected target cells, referred to as cyto-
toxicity, has been attributed to CD8+ T cells. However, recently, 
interest in the cytotoxic capacity of CD4+ T  cells has been 
revived. In mice and humans, it has been shown that cytotoxic 
CD4+ T  cells play protective roles in cytomegalovirus (CMV) 
infections (5, 6). While the population of cytotoxic CD4+ T cells 
is less abundant than that of cytotoxic CD8+ T cells, cytotoxic 
CD4+ T  cells are as capable as their CD8+ equivalents in the 
killing of target cells (7–9).
Early during infection, human CMV (hCMV)-specific CD4+ 
T  cells were demonstrated to produce IFNγ and exhibit a TH1 
phenotype. During the course of infection, these TH1-type CD4+ 
T  cells acquire a cytotoxic profile, lose CD27 and CD28, and 
obtain granzyme B (10). Furthermore, these cells gain the ability 
to lyse infected target cells in an HLA class II-dependent manner 
(7). The cytotoxic CD4+ T cells retained the capacity to produce 
IFNγ and also co-produced a multitude of other cytokines, 
including TNFα. Only recently, HLA class II tetramers have 
become available that allow for the identification and phenotyp-
ing of antigen-specific CD4+ T cells directly ex vivo (11). Using 
HLA class II tetramers, hCMV-specific CD4+ T cells have been 
described to conform to the effector-like phenotype with high 
cytotoxic potential. Similar to their cytotoxic CD8+ counterparts, 
the hCMV-specific CD4+ T  cells contain lytic granules loaded 
with granzyme B and perforin that mediate lysis of infected 
target cells. Cytotoxic hCMV-specific CD4+ T cells also express 
CX3CR1, which may direct migration to inflamed endothelium, 
a major site of hCMV infection (12, 13).
Previously, we have shown that the transcription factor 
Homolog of Blimp-1 in T cells (Hobit) is upregulated in CD45RA+ 
effector-type CD8+ T  cells as well as in hCMV-specific CD8+ 
T  cells that display the phenotype of CD45RA+ effector-type 
CD8+ T cells. We have also demonstrated that Hobit is involved 
in the transcriptional regulation of effector functions, including 
the production of IFNγ and granzyme B (14, 15). As the char-
acteristics of cytotoxic CD8+ and CD4+ T cells strongly overlap, 
we hypothesized that these cells share a transcriptional program. 
In search of relevant transcriptional regulators of cytotoxicity in 
CD4+ T cells, we set out to investigate the involvement of Hobit 
in the regulation of cytotoxic CD4+ T cells.
resUlTs
hobit is expressed in cD4+cD28− effector-
Type T cells
Using microarray analysis, we have previously identified Hobit, 
encoded by ZNF683, as one of the most distinctly expressed 
transcription factors in CD45RA+ effector CD8+ T  cells (16). 
To investigate the expression pattern of Hobit in CD4+ T  cell 
differentiation, we isolated CD4+ T  cells from the peripheral 
blood of healthy donors. Effector CD4+ T cell differentiation is 
characterized by the stepwise loss of CD27 and CD28 (10, 12) 
and, therefore, we sorted CD4+ T  cells into three populations 
based on the expression of the co-stimulatory molecules CD28 
and CD27. Naïve T cells co-express CD27 and CD28, intermedi-
ately differentiated cells downregulate CD27, but not CD28, and 
terminally differentiated cytotoxic CD4+ T cells are characterized 
by the lack of these two molecules (10, 17, 18). We used qPCR 
to analyze the expression of Hobit mRNA. Hobit expression was 
high in cytotoxic CD4+CD28−CD27− T cells, but nearly absent in 
CD4+CD28+CD27+ and CD4+CD28+CD27− T cells (Figure 1A). 
As Hobit has high homology with Blimp-1, which has been shown 
to regulate effector T  cell differentiation in mice (19), we also 
assessed the expression of Blimp-1 in the three CD4+ T cell popu-
lations. In contrast to Hobit, Blimp-1 was equally upregulated in 
intermediately and terminally differentiated CD4+ T cells subsets 
compared to CD4+CD27+CD28+ T cells (Figure 1B). Reflecting 
the mRNA analysis, Hobit protein expression was found in ter-
minally differentiated, but not in other CD4+ T cells (Figure 1C). 
Cytotoxic CD4+ T cells are described to express either CD45RA 
or CD45RO (10, 12, 13). Hobit was uniformly expressed by CD4+ 
effector T cells (CD45RA+CD27−) and by a fraction of effector 
memory CD4+ T cells (CD45RA−CD27−) (Figure 1D).
hobit+ cD4+ effector-Type cells Display  
a cytotoxic Profile
In order to further characterize the cytotoxic potential of Hobit+ 
CD4+ T  cells, we addressed the expression of proteins that are 
required for the killing of target cells. We found that both perforin 
and granzyme A and B are highly co-expressed with Hobit, with 
approximately 75% of Hobit+ CD4+ T cells expressing perforin, 
granzyme A, and/or B (Figures 2A–C). In contrast, the cytotoxic 
molecule granzyme K did not associate with Hobit (Figure 2D). 
This result is supported by previous reports showing that gran-
zyme K, in contrast to Hobit, is not abundantly expressed in effec-
tor CD8+ T cells (20). To further investigate the characteristics of 
Hobit+ T cells, we assessed the association of this transcription 
factor with key properties of cytotoxic T cells. CX3CR1 has been 
shown to mark cytotoxic CD4+ and CD8+ T cells and direct them 
toward fractalkine on activated endothelium (21, 22). It was 
also recently reported that hCMV-specific CD4+ T cells express 
CX3CR1 (12). We demonstrate that the majority of Hobit+ CD4+ 
and CD8+ T  cells express CX3CR1 (Figure  2E). Of interest is 
that, vice versa, nearly all of the CX3CR1+ CD4+ and CD8+ T cells 
express Hobit (data not shown).
Previously, CD4+ effector T cell differentiation was shown 
to be associated with the loss of the chemokine receptor 
CCR7 (7, 10), which mediates the migration of immune cells 
to secondary lymphoid organs. As Hobit directly suppresses 
CCR7 expression of lymphocytes in mice (14), we analyzed the 
expression of this chemokine receptor by human Hobit+ T cells. 
In contrast to the Hobit− fraction, the Hobit+ CD4+ and CD8+ 
T cells lacked CCR7 expression (Figure 2F). These data suggest 
that Hobit+ T cells do not respond to CCR7-dependent signals 
that instruct homing to lymphoid organs, in line with the 
observation that cytotoxic CD4+ and CD8+ T cells are absent 
from this compartment (20).
KLRG1 and CD127 are frequently used to differentiate between 
memory (precursor) cells (KLRG1−CD127+) and effector cells 
(KLRG1+CD127−) (23). In line with effector differentiation, we 
FigUre 1 | hobit is expressed in cD4+cD28−cD27− effector-type T cells. Total CD4+ T cells can be divided in three fractions based on the expression of 
CD28 and CD27. (a,B) Healthy donor peripheral blood-derived CD4+ T cells were sorted based on the expression of CD28 and CD27 and RNA was isolated. Hobit 
(a) and Blimp-1 (B) mRNA was measured by qPCR. Values are depicted relative to 18S and calibrated using naïve CD4+ T cells. (c,D) Hobit expression was 
identified in different CD4+ T cell subsets based on (c) the expression of CD27 and CD28 or (D) based on the expression of CD45RA and CD27. Representative 
contour plots are depicted on the left. Stacked histograms (maximum set to 100%) for the color indicated subsets are depicted in the center panels. On the right, 
the quantification of the percentage of Hobit+ cells in the different populations is displayed (n = 9). **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with 
Holm–Sidak’s multiple comparisons test.
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found that the majority of the Hobit+ CD4+ T  cells and CD8+ 
T cells expressed KLRG1 (Figure 2G). Strikingly, the majority of 
the Hobit+CD4+ T cells also expressed CD127, while this molecule 
was absent on Hobit+CD8+ T  cells (Figure  2H). However, the 
mean fluorescence intensity of CD127 was lower in Hobit+CD4+ 
T cells than in Hobit−CD4+ T cells (Figure S1 in Supplementary 
Material). These findings suggest that Hobit+CD4+ T  cells 
downregulate CD127 similar to effector CD8+ T cells, but that 
the downregulation is incomplete. Homeostatic IL-7 signaling for 
the maintenance of T cells is mediated by CD127, encoding the 
IL-7Rα chain (24) indicating that Hobit+CD4+ T cells may rely on 
homeostatic IL-7 signaling for their maintenance.
It has been previously demonstrated that the transcrip-
tion factors T-bet and Eomes are essential for the formation 
and maintenance of CD8+ effector T  cells. Hobit expression 
strongly overlaps with that of T-bet in CD8+ effector T cells (25). 
Similarly, we observed a high degree of overlap between Hobit 
and T-bet expression in CD4+ T cells, with up to 98% of Hobit+ 
cells-expressing T-bet (Figure 2I). Strict co-expression was not 
observed between Hobit and Eomes. CD4+ T cells that expressed 
Eomes were Hobit+ (data not shown), but not all Hobit+ CD4+ 
T cells expressed Eomes (Figure 2J). In the case of CD8+ T cells, 
there is substantial co-expression of Hobit and Eomes; however, 
Hobit− CD8+ T cells that express Eomes also exist.
FigUre 2 | hobit+ cD4+ effector-type cells display a cytotoxic profile. (a-J) Representative histograms (maximum set to 100%) and quantification of the 
expression of perforin (a), granzyme B (B), granzyme A (c), granzyme K (D), CX3CR1 (e), CCR7 (F), KLRG1 (g), CD127 (h), Tbet (i), and Eomes (J) by Hobit+ (in 
red) and Hobit− (in black) CD8+ (left column) and CD4+ T cells (right column). Box and whiskers plots show the percentage of Hobit+ and Hobit− non-naïve CD4+ 
T cells expressing the different molecules (n = 4–10). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; paired T-test.
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Together, these data demonstrate that Hobit expression 
identifies CD4+ T cells with a cytotoxic profile, suggesting that 
Hobit is a key mediator of CD4+ effector T cell differentiation. 
The phenotype of Hobit+ CD4+ T  cells parallels that of Hobit+ 
CD8+ T cells, suggesting a common transcriptional program of 
cytotoxicity between the two lineages.
FigUre 3 | human cytomegalovirus (hcMV)-specific cD4+ T cells 
express hobit. The expression of Hobit was analyzed in hCMV-specific 
CD4+ T cells using class II tetramers. (a) Populations of hCMV-specific CD4+ 
T cells were identified in three donors using three different tetramers, 
indicated by the first three letters of the peptide sequence (LLQ, AGI, and 
DYS). The contour plots show total PBMCs with CD4 on the x-axis and 
tetramer on the y-axis. (B) The histograms show the expression of Hobit on 
CD4+ tetramer+ T cells (red) and CD4+ tetramer− T cells (black) of three 
donors.
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hcMV-specific cD4+ T cells express hobit
As hCMV induces the differentiation of cytotoxic CD4+ 
T cells, we analyzed the expression of Hobit in hCMV-specific 
CD4+ T cells of hCMV-seropositive donors using HLA class II 
tetramers specific for various hCMV epitopes. The frequencies 
of hCMV-specific CD4+ T cells varied between 0.1 and 4.6% of 
total T  cells in the three different individuals (Figure  3A), the 
hCMV-specific CD4+ T cells recognizing the analyzed epitopes 
all expressed Hobit to a substantial degree (Figure 3B), similar to 
hCMV-specific CD8+ T cells, as we have previously shown (25). 
Thus, the hCMV-driven differentiation of cytotoxic CD4+ T cells 
includes the upregulation of Hobit expression.
hobit+ cD4+ T cells increase over Time 
during Primary hcMV infection In Vivo
To investigate Hobit expression after primary hCMV infection, 
we analyzed CD4+ T cells in samples derived from three hCMV-
seronegative recipients who had received hCMV-positive kidney 
transplants at least 35 weeks ago. As hCMV infection is known to 
also induce the expansion of CD8+ and γδ+ effector T cells (26, 27), 
we analyzed these T cell lineages in parallel to the CD4+ T cells. In 
one patient (pt 153), Hobit expression within CD4+ T cells and the 
abundance of Hobit+ CD4+ T cells remained low compared to the 
massive expansion of Hobit+ γδ+ and CD8+ T cells (Figures 4A,B). 
Although the CD4+ response was low, it still passed the threshold 
of 0.5% cytotoxic CD28−CD4+ T  cells previously shown to be 
the minimal indication of hCMV infection (10). In contrast, the 
other two patients (pt 156 and 333) showed a substantial expan-
sion of Hobit+ cells within the CD4+ T cell compartment as well 
as the CD8+ and γδ+ T cell compartments (Figures 4A,B). We 
analyzed the kinetics of the expansion of the three T cell lineages 
further (Figures  4C–G; Figure S2 in Supplementary Material). 
The accumulation of Hobit+ CD4+ T cells only started after clear-
ance of viral infection between weeks 11 and 13 (Figures 4C,F). 
After about 15 weeks, the Hobit-expressing CD4+ T cell popula-
tion stabilized at around 40% of CD4+ T cells and 10% of total 
lymphocytes (Figures 4F,G). These findings closely correspond 
with the kinetics of the emergence of a CD4+CD28− population 
after hCMV infection (10). Furthermore, the kinetics of the CD4+ 
effector response appeared similar to that of the effector CD8+ 
T cell and γδ+ T cell response, except that the overall magnitude 
was lower for the response of the CD4+ and γδ+ T cells than for 
that of the CD8+ T cells (Figures 4C–G).
hobit identifies cD4+ effector-Type T cells 
during Primary hcMV infection In Vivo
Surface expression of CD45RA and CD27 defines naïve 
(CD45RA+CD27+), memory (CD45RA−), and effector 
(CD45RA+CD27−) T cells. As expected during the latency stage 
of infection (week 28 and onward), the majority of Hobit+ CD4+ 
T cells expressed an effector phenotype (Figure 5A). In contrast, 
pretransplant and at early time points posttransplant, Hobit+ 
CD4+ T cells are mainly characterized by a memory phenotype. 
The Hobit+ CD4+ T cells first downregulate CD27 at around week 
11, followed by the upregulation of CD45RA at around week 15, 
thereby completing the acquisition of the effector phenotype. 
Similar downregulation of CD27 preceding the upregulation of 
CD45RA was found for Hobit+ CD8+ and Hobit+ γδ+ T cells, albeit 
with faster kinetics (Figures 5B,C). Importantly, the phenotypic 
composition of the Hobit− CD4+, CD8+, and γδ+ T cell popula-
tion stably represented naïve and memory T cells throughout the 
sampling period (Figure S3 in Supplementary Material), suggest-
ing that the events in T cell differentiation during the course of 
hCMV infection are restricted to the Hobit+ cells. Taken together, 
these data suggest that Hobit expression precedes the develop-
ment of terminally differentiated effector T cells, which supports 
an instructive role of the transcription factor in the acquisition of 
the effector profile.
Transcriptional Programming of cytotoxic 
cD4+ T cells
The parallels between cytotoxic CD4+ and CD8+ T cells prompted 
us to compare the transcriptional profiles of these cells. Therefore, 
we made a comparison of the microarray data on hCMV-specific 
CD4+ T cells (12) with microarray data on CD8+ T cells during 
a primary hCMV response (16). We found substantial overlap 
between the transcriptional profiles of the effector CD4+ and 
CD8+ T cells (Figure 6A). The CD4+ microarray did not include 
the probe set for ZNF683 (Hobit), which excluded Hobit from 
the comparison. Genes encoding perforin, granzyme B, CX3CR1, 
Tbet, CD27, and CCR7 (highlighted in red) were similarly regu-
lated in cytotoxic CD4+ and CD8+ T cells (Figure 6A), in contrast 
to genes encoding the IL-7R and CD28 (also highlighted in red). 
FigUre 4 | hobit+ cD4+ T cells increase over time during primary human cytomegalovirus (hcMV) infection in vivo. The induction of Hobit expression in 
CD4+, CD8+, and γδ+ effector type T cells was followed over the course of primary hCMV infection. (a) Frequency of Hobit+ cells of CD4+, CD8+, and γδ+ T cells 
within the population and (B) the abundance of Hobit+CD4+, Hobit+CD8+, and Hobit+γδ+ in the total CD3+ T cells in three hCMV-seronegative recipients (pt153, 
pt156, and pt333) was analyzed at more than 35 weeks after kidney transplantation from a hCMV-seropositive donor. The dotted line in (a) indicates the percentage 
of cytotoxic CD4+ T cells minimally induced by hCMV infection. (c–e) The overlayed histograms (maximum set to 100%) demonstrate the kinetics of Hobit 
expression in total (c) CD4+, (D) CD8+, and (e) γδ+ T cells over the course of primary hCMV infection in pt333. On the right, the sampling time points are indicated 
in weeks (w) posttransplantation. The color code indicates the percentage of Hobit+ cells according to the depicted key. (F) The line graph shows the induction of 
Hobit expression (left y-axis) in CD4+ (white), CD8+ (black), and γδ+ (gray) T cells after kidney transplantation in pt333. The x-axis shows the weeks 
posttransplantation. Viral loads (determined by qPCR and in light gray) is plotted on the right y-axis as copies of hCMV per milliliter of blood. (g) The abundance of 
the Hobit+CD4+, Hobit+CD8+, and Hobit+γδ+ in the total CD3+ T cells is shown over the course of the hCMV infection for pt333.
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These findings largely substantiate our results as the products of 
these genes except for the IL-7R associated with Hobit in both 
CD4+ and CD8+ T cells (Figures 1 and 2).
Within the shared up- and downregulated genes, we also 
identified known targets of Hobit that include GZMB, CCR7, 
and TCF7 (14, 15). To confirm the microarray data, we sorted 
CD28−CD27−, CD28+CD27−, and CD28+CD27+ CD4+ T  cells 
and performed qPCRs for these Hobit targets (Figure 6B). We 
found that GZMB was exclusively expressed in the CD28−CD27− 
subset, while mRNA expression of CCR7 and TCF7 was low in 
this subset, intermediate in the CD28+CD27− subset, and high 
in the CD28+CD27+ subset. These findings are in line with a role 
for Hobit in the regulation of the transcriptional program of 
cytotoxic CD4+ T cells.
FigUre 5 | hobit identifies expanded cD4+ effector-type T cells during primary human cytomegalovirus (hcMV) infection in vivo. The distribution of 
CD45RA/CD27 expression by Hobit+ (a) CD4+, (B) CD8+, and (c) γδ+ T cells was characterized over the course of hCMV infection for pt333. Top panels show 
contour plots of CD45RA/CD27 of Hobit+ T cells for the indicated time points after transplantation (weeks). Lower panels show pie charts representing the 
distribution of CD45RA/CD27 expression by Hobit+ T cells of the three lineages.
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DiscUssiOn
Transcription factors initiate differentiation processes by 
instructing lineage-specific gene programs. Therefore, they 
are interesting candidates in the identification of cell subsets 
through their expression profiles that are strongly associated with 
unique cell populations. In this report, we have identified the 
transcription factor Hobit as a marker of cytotoxic CD4+ T cells 
in humans. Hobit is expressed by all cytotoxic CD4+ T  cells, 
but absent from other CD4+ T  cell populations in peripheral 
FigUre 6 | Transcriptional profile of cytotoxic cD4+ T cells. The transcriptional profile of cytotoxic CD4+ T cells was determined by comparing the signature of 
human cytomegalovirus (hCMV)-specific CD4+ T cells to effector CD8+ T cells during a primary hCMV infection. (a) The dot plot shows the genes that are up- and 
downregulated by hCMV-specific CD4+ T cells compared to CMV-effector CD4+ T cells on the y-axis and the genes that are up- and downregulated by effector 
CD8+ T cells in a primary hCMV infection compared to naive CD8+ T cells on the x-axis. The changes shown are on a log2 scale on both axes. The differentially 
regulated genes in either comparison are depicted in grey except for the genes described at protein level in Hobit+CD4+ T cells in Figures 1 and 2, which are shown 
in red. (B) The specific target genes of Hobit that were differentially expressed, GZMB, CCR7, and TCF7 were confirmed by qPCR in sorted CD4+ T cell subsets 
(CD28+CD27+, CD28+CD27−, CD28−CD27−). The values are depicted as relative to 18S and calibrated to naïve CD4+ T cells. For the qPCR data, n = 4. *p < 0.05; 
one-way ANOVA with Holm–Sidak’s multiple comparisons test.
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blood including regulatory T cells, as described previously (25). 
Expression of Hobit in CD4+ T cells on its own was sufficient to 
adequately identify cytotoxic CD4+ T cells, suggesting that the 
transcription factor is a useful alternative for the identification 
of these cells. The advantage of Hobit over the classical defini-
tion of cytotoxic CD4+ T  cells using CD27 and CD28 is that 
in contrast to these co-stimulatory molecules, Hobit acts as a 
positive marker, which improves the accuracy of the typing of 
these cytotoxic CD4+ T cells. Furthermore, as Hobit expression 
precedes development of effector-type CD4+ T cells, Hobit may 
allow for earlier recognition of the expanding cytotoxic CD4+ 
T cell population.
Hobit is also expressed outside of the CD4+ T  cell lineage 
in CD45RA+ effector CD8+ T cells and CD56dim NK cells (25). 
Interestingly, here, we showed that the spectrum of Hobit+ 
lymphocytes also includes effector γδ+ T cells. Similar to Hobit+ 
CD4+ T cells, these Hobit+ populations within the CD8+ T cell, 
γδ+ T  cell, and NK  cell lineages are cytotoxic lymphocytes 
that maintain constitutive protein expression of granzyme B 
and perforin. The overlap in the expression profiles between 
9Oja et al. Hobit Identifies Cytotoxic CD4+ T Cells
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the cytotoxic populations of lymphocytes extends beyond the 
expression of cytotoxic molecules and includes the down-
regulation of CD27, CD28, and CCR7 and the upregulation of 
CX3CR1 and T-bet. The similarity in phenotypes suggests that 
these cytotoxic lymphocytes are under the control of overlap-
ping transcriptional programs. Currently, direct evidence for 
a role of Hobit in the transcriptional regulation of cytotoxicity 
in human lymphocytes is not available. Given that we have 
previously shown that Hobit is essential for the upregulation of 
granzyme B expression in NKT cells in mice (15), it is conceiv-
able that Hobit also instructs the cytotoxic program of human 
lymphocytes. In support of an instructive role of Hobit in cyto-
toxic CD4+ T cells, we found that granzyme B and other target 
genes of Hobit, including CCR7 and TCF7, were up- or down-
regulated at the transcript level in these cells. The co-expression 
of T-bet and Hobit, and to a lesser extent Eomes, suggests that 
these transcription factors may concordantly contribute to the 
transcriptional regulation of the cytotoxic program in human 
cytotoxic lymphocytes.
CD4+ T cells with a cytotoxic phenotype arise after primary 
infection with hCMV in humans (7, 10, 28). Peptide restimula-
tion, proliferation, and tetramer studies have also identified 
hCMV-specific cells within the population of cytotoxic CD4+ 
T  cells (7, 10, 12). It has been suggested that cytotoxic CD4+ 
T cells have arisen to provide an additional layer of HLA class 
II-dependent protection in response to the immune evasive 
strategies of the hCMV virus that are targeted at CD8+ T cell and 
NK cell-driven immunity (7). We describe that the CD4+ T cells 
that accumulate after primary hCMV infection in transplant 
patients express Hobit, suggesting that upregulation of Hobit is an 
integral part of the cytotoxic CD4+ T cell response against hCMV. 
Furthermore, our class II tetramer studies directly showed that 
hCMV-specific CD4+ T  cells nearly uniformly express Hobit. 
At this time, it remains unclear, which signals drive the expres-
sion of Hobit in cytotoxic CD4+ T cells after hCMV infection. 
Previously, we have described that T-bet and IL-15 induce Hobit 
expression in murine CD8+ T cells (14). Consistent with these 
findings, T-bet and Hobit are strongly co-expressed in human 
CD4+ T  cells and, as described previously, in human CD8+ 
T  cells (25). Antigenic stimulation downregulates expression 
of Hobit in NKT cells (15). Interestingly, the Hobit+CD4+ T cell 
response demonstrated relative similar kinetics as the CD8+ and 
γδ+ T cell responses after resolution of primary hCMV infection, 
suggesting that antigenic stimulation also antagonizes Hobit 
expression in human T cells. Thus, it is plausible that, after viral 
clearance, T-bet mediates the upregulation of Hobit expression 
in CD4+ T cells.
Similar to CD45RA+ effector CD8+ T cells, cytotoxic CD4+ 
T cells are long-lived and highly effective in the elimination of 
infected target cells (7). The combination of these useful proper-
ties suggests that cytotoxic CD4+ T  cells may be of potential 
interest in adoptive transfer strategies for the treatment of 
patients. However, many hurdles need to be overcome before 
cytotoxic CD4+ T  cells can be used in cellular therapy. CD4+ 
T cells appear fragile after isolation, do not robustly expand after 
TCR stimulation, and may be difficult to maintain on homeo-
static cytokines such as IL-7 due to low expression of CD127. 
Therefore, a better understanding of the role of Hobit in the 
differentiation pathway of these cells may be instrumental to 
improve protocols for the formation and expansion of cytotoxic 
CD4+ T cells.
MaTerials anD MeThODs
subjects
PBMCs were isolated from buffy coats of healthy donors sup-
plied by Sanquin Blood Supply Foundation. The CMV status 
of the healthy donors is unknown. We also received samples 
longitudinally from one kidney transplant patient (patient 156) 
who was seronegative for Epstein–Barr virus (EBV) and hCMV 
prior to the transplant. We also received samples from two patient 
kidney transplant patients (patient 153 and 333) who were EBV 
seropositive but hCMV seronegative prior to the transplant. Two 
of the patients (patient 153 and 333) developed a primary hCMV 
infection while the other (patient 156) developed a primary EBV 
and hCMV infection after receiving a kidney from an EBV+ and 
hCMV+ donor. The patients received immunosuppressive treat-
ment, including prednisolone, cyclosporine A, and mycopheno-
late mofetil.
ethics statement
Written informed consent was given by all of the patients. The 
Amsterdam Medical Center Medical Ethical Committee approved 
the study according to the Declaration of Helsinki.
isolation of Mononuclear cells from 
Peripheral Blood
PBMCs were isolated from heparinized peripheral blood samples 
with standard density gradient centrifugation method and cryo-
preserved until further analysis.
Flow cytometric cell sorting
For the analysis of Hobit, Blimp1, GZMB, CCR7, and TCF7 
mRNA, CD3+CD4+CD28+CD27+, CD3+CD4+CD28+CD27−, 
and CD3+CD4+CD28−CD27− T  cells were isolated using flow 
cytometric sorting for CD3, CD4, CD28, and CD27 using FACS 
Aria (BD).
Quantitative Pcr
RNA was isolated from the sorted samples using Invisorb RNA 
isolation kit (Invitek) or Trizol reagent (Invitrogen). cDNA was 
synthesized using RevertAID H Minus Reverse Transcriptase 
(Thermo Scientific) and random primers (Invitrogen) or poly dT 
oligos (Invitrogen). qPCR analysis was performed using Power 
SYBR Green (Applied Biosystem) with StepOnePlus Real-Time 
PCR system (Applied Biosystem). The following primers were used: 
Hobit (forward: 5′-CATATGTGGCAAGAGCTTTGG-3′, reverse: 
5′-AGAGCTTCACTCAACTTGCC-3′), Blimp-1 (forward: 5′-C 
AACAACTTTGGCCTCTTCC-3′, reverse: 5′-GCATTCATG 
TGG CTTTTCTC-3′), GZMB (forward: 5′- TGCGAATCTGA 
CTTACGCCAT-3′, reverse: 5′- GGAGGCATGCCATTGTTT 
CG-3′), CCR7 (forward: 5′- CAGCCTTCCTGTGTGGTTTT-3′, 
reverse: 5′- AAATGACAAGGAGAGCCACC-3′) and TCF7 
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(forward: 5′-AGAGAGAGAGTTGGGGGACA-3′, reverse: 5′-TC 
TGCTCATGCATTACCCAC-3′), and 18S (forward: 5′-GGAC 
AACAAGCTCCGTGAAGA-3′, reverse: 5′- CAGAAGTGACGC 
AGCCCTCTA-3′). Values are depicted as relative to 18S and 
calibrated to naïve CD4+ T cells.
Flow cytometry analysis
PBMCs were labeled with different combinations of the follow-
ing antibodies: CD4 BUV737 (BD, clone SK3), CD8 BV786 (BD, 
clone RPA-T8), CD8 BUV805 (BD, clone SK1), CD3 V500 (BD, 
clone UCHT1), CD3 eVolve605 (eBioscience clone OKT3), CD27 
APC-eFluor780 (eBioscience, clone), CD27 BV510 (Biolegend, 
clone O323), CD45RA BV650 (BD, clone HI100), CD45RA 
Qdot655 (Invitrogen, clone MEM-56), CD28 PE-Cy7 (BD, clone 
28.2), CX3CR1 APC (eBioscience, clone 2A9-1), CCR7 BV421 
(Biolegend, clone G043H7), CD127 BV421 (Biolegend, clone 
A019D5). Near-IR fixable dye (Invitrogen) was used to exclude 
dead cells from the analysis. For intracellular staining, the fol-
lowing antibodies were used: Hobit IgM (BD, clone Sanquin-
Hobit/1), Eomes eFluor660 (eBioscience, clone WD1928), Tbet 
BV421 (Biolegend, clone 4B10), Granzyme B AF700 (BD, clone 
GB11), Perforin FITC (eBioscience, clone dG9), Perforin PE 
(eBioscience, clone B-D48), Granzyme K PE (Immunotools, 
clone 24C3), Granzyme K FITC (Immunotools, clone 24C3). 
To stain for Hobit IgM, a secondary anti-IgM labeled with PE 
or FITC was used. The cells were labeled according to manufac-
turer’s instructions. For the intracellular staining, the cells were 
fixed and permeabilized using the Foxp3/Transcription Factor 
Staining kit (eBioscience). The samples were measured in PBS 
0.5% FCS with a LSR Fortessa (BD). The analysis was done using 
FlowJo Version 10 software.
class ii Tetramer analysis
The class II tetramers used in this study and the staining protocol 
were previously described by Pachnio et  al  (12). Briefly, three 
tetramers were used against three different hCMV epitopes; 
gB-derived epitope DYSNTHSTRYV (HLA-DRB1*07:01) 
and pp65-derived epitopes AGILARNNLVPMVATV (HLA-
DRB3*02:02) and LLQTGIHVRVSQPSL (HLA-DQB1*06:02).
statistics
To determine the significance of our results, we used the paired 
T-test or one-way ANOVA and Holm–Sidak’s multiple com-
parisons test using GraphPad Prism 6. A p-Value of less than 
0.05 was considered statistically significant (*p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001).
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